State of Health

Can you stop antibiotics for endocarditis two weeks early? The POET II trial (NEJM 2026) tested a protocol-based stopping rule in 508 patients.In stable patients with left-sided endocarditis from streptococci, Staphylococcus aureus or Enterococcus faecalis, stopping antibiotics once the POET stabilization criteria were met cut treatment by about two weeks and met noninferiority for the composite of death, unplanned surgery and embolism at six months. Relapse rose from 1.6 to 5.1 percent, mostly manageable, with enough enterococcal signal to argue for caution there. This supports considering a shorter course in selected patients, with close follow-up and a frank discussion of relapse.Original article: https://doi.org/10.1056/NEJMoa2607887

The BRONCHIOLE trial found that adding metoprolol to standard care did not significantly reduce exacerbations, cardiovascular events, or death in patients with COPD and no heart disease. It also found no rise in hospitalized exacerbations or deaths. The practical takeaway: don't start a beta-blocker to treat COPD itself, but don't withhold one from a COPD patient who needs it for their heart.Original article: Sundh J, et al. NEJM Evidence 2026. https://doi.org/10.1056/EVIDoa2600231ABOUT THE STATE OF HEALTHThe State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠FOLLOW USYoutube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Threads: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠threads.net/@medzcool

Explore groundbreaking advancements in treating hereditary angioedema with NTLA 2002, a revolutionary CRISPR-Cas9 therapy. Discover how this innovative one-time treatment significantly reduces attacks, offering hope for those affected by this rare condition. Original Article here. ABOUT THE STATE OF HEALTH The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FOLLOW US Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Threads: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠threads.net/@medzcool

The ARTESIA trial demonstrates that Apixaban effectively reduces the risk of stroke or systemic embolism in patients with subclinical atrial fibrillation. Despite the increased risk of major bleeding, the severity of prevented stroke events outweighs the severity of bleeding events caused by the drug. This could potentially change the approach to managing subclinical atrial fibrillation in patients at high risk of stroke. Original article here. ABOUT THE STATE OF HEALTH The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FOLLOW US Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Threads: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠threads.net/@medzcool

This episode delves into a five-year study comparing the effectiveness of TAVR versus traditional surgery in treating low-risk aortic stenosis patients. Original article here. ABOUT THE STATE OF HEALTH The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FOLLOW US Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Threads: ⁠⁠⁠⁠⁠⁠⁠⁠⁠threads.net/@medzcool

We explore the groundbreaking trial of Amivantamab combined with chemotherapy in treating non-small-cell lung cancer - specifically those presenting the EGFR exon 20 insertions. We delve into the trial's promising results, the significant increase in progression-free survival, and the potential of this new approach to revolutionize lung cancer treatment. Original article here. ABOUT THE STATE OF HEALTH The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FOLLOW US Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠ Threads: ⁠⁠⁠⁠⁠⁠⁠⁠threads.net/@medzcool

We discuss a clinical trial's findings on the use of intravenous levothyroxine on unstable, brain-dead heart donors, and how these findings may impact organ donation and transplantation practices. Original article here. ABOUT THE STATE OF HEALTH The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FOLLOW US Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠⁠ Threads: ⁠⁠⁠⁠⁠⁠⁠threads.net/@medzcool

We delve into the results of the GRADUATE I and II trials, examining the impact of Gantenerumab, a human monoclonal antibody, on early Alzheimer's disease. We explore how its efficacy in reducing amyloid plaques failed to significantly alter the course of cognitive decline, while also discussing potential implications for future Alzheimer's disease treatments. Original article here. ABOUT THE STATE OF HEALTH The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FOLLOW US Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠ Threads: ⁠⁠⁠⁠⁠⁠threads.net/@medzcool

The MINT trial compares liberal and restrictive transfusion strategies in patients with acute myocardial infarction and anemia. Findings suggest potential benefits of a liberal approach, prompting further research. Original article here. ABOUT THE STATE OF HEALTH The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FOLLOW US Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠ Threads: ⁠⁠⁠⁠⁠⁠threads.net/@medzcool

Exploring the role of Elafibranor in Primary Biliary Cholangitis (PBC) treatment, this podcast delves into the significant findings of the ELATIVE trial, highlighting its potential as an effective and safe second-line treatment option for patients who have had inadequate responses or side effects with Ursodeoxycholic acid. Original article here. ABOUT THE STATE OF HEALTH The State of Health helps you understand the most important news and research in healthcare and medicine. For more visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠stateofhealth.care⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ FOLLOW US Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@medzcool⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/medzcool⁠⁠⁠⁠⁠⁠⁠ Threads: ⁠⁠⁠⁠⁠⁠threads.net/@medzcool